Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KLAC$130.53-19.12(-12.78%)KLA Declares Regular Cash Dividend4:30:14 PM ETMU$665.03-130.43(-16.40%)Micron Announces Board of Directors Retirement4:30:06 PM ETMU$665.03-130.43(-16.40%)Micron Announces Board of Directors Retirement4:30:00 PM ETKO$95.78-0.10(-0.10%)DRIVX Moves Toward Final Presale Stage, Unveils Fleet Expansion and Transparent Vesting Strategy4:19:08 PM ETCRWD$218.60-22.38(-9.29%)Why CrowdStrike and cybersecurity stocks got crunched in Thursday's rout4:12:00 PM ETNVDA$182.50-17.79(-8.88%)Nvidia's Huang is asked to brief Congress on reported Chinese spy relationship4:09:56 PM ETLRCX$191.05-30.23(-13.66%)Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend4:05:00 PM ETSKHY$124.32-18.76(-13.11%)Why SK Hynix Plunged Today4:01:39 PM ETNVDA$182.50-17.79(-8.88%)Is Nvidia Still a Millionaire-Maker Stock?3:51:00 PM ETTSLA$341.91-43.27(-11.23%)SpaceX and Tesla Stock Plunges Have Wiped About $450 Billion in Value Since the Midterms. Is It Time to Buy?3:43:35 PM ETGOOGL$280.14-8.89(-3.08%)Google plans $17 billion Wyoming data center amid rising threats of curbs3:43:13 PM ETNOW$101.21-7.70(-7.07%)Arista Networks vs. ServiceNow: Which Technology Stock Is a Better Buy for 2027?3:43:02 PM ETGOOGL$280.14-8.89(-3.08%)BREAKINGVIEWS-Global muscle will sift puny data center providers3:30:09 PM ETAMD$408.18-80.51(-16.47%)Is AMD Stock a Buy as AI Revenue Soars?3:19:00 PM ETGEV$770.56-61.95(-7.44%)GE Vernova vs. NextEra Energy: Which Industrials Stock Is a Better Buy for 2027?3:17:11 PM ETBRK-A$857,487.54-9,063.79(-1.05%)Berkshire Hathaway Reports Nov. 7 With Its Stock at a Record. Its Cash Pile Is the Number to Watch.3:17:02 PM ETC$118.48+0.68(+0.58%)UPDATE 10-Brent crude jumps, settles up over $3 after tanker attacks3:15:37 PM ETCLX$99.10-0.10(-0.10%)Global Surface Disinfectant Market to Hit US$ 7.5 Bn by 2031, Registering at 7.4% CAGR: Wissen Research3:14:00 PM ETTM$218.30+18.94(+9.50%)ERI’s John Shegerian Describes the Current State of Rare Earth Mineral Recovery at World Remanufacturing Summit in Tokyo3:09:00 PM ETMRVL$135.35-24.56(-15.36%)Marvell Just Dropped 49% in a Month: Is MRVL Stock Hopeless or Ready for a Rebound?3:03:21 PM ETSPCX$123.50-12.33(-9.08%)Bull v. Bear: SPCX Faces Uncertainty as Midterm Results Pressure TSLA Merger3:00:38 PM ETINTC$52.09-6.19(-10.62%)Intel Shares Rise 6% To Intraday High After Key Trading Signal3:00:27 PM ETAMD$408.18-80.51(-16.47%)Advanced Micro Devices vs. Taiwan Semiconductor Manufacturing: The AI Sell-Off Is Exposing a Critical Difference Investors Shouldn't Ignore for 20273:00:02 PM ETHSY$177.43+2.93(+1.68%)Hershey vs. Coca-Cola: Which Consumer Goods Stock Is a Better Buy for 2027?2:51:29 PM ET

AMPH · NASDAQ

Amphastar Pharmaceuticals, Inc.

$30.10 +2.08 (+7.42%)

Company overview

Amphastar Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Market cap
$1.3B
Employees
2,028
Headquarters
Rancho Cucamonga, CA
Website
amphastar.com
CEO
Yongfeng Zhang
Listed
June 25, 2014
P/E
17.54
Dividend yield
3.43%

Company financials

Revenue
$721M
Gross profit
$341M
Operating income
$117M
EBITDA
$156M
Net income
$79.2M
EPS
$1.71
Total assets
$1.6B
Total debt
$686M
Gross margin
47.34%
Net margin
11.00%
Earnings yield
5.70%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

16.1719.3922.6125.8229.04
AMPH 1D NASDAQ O27.37H28.57L27.09C28.02+0.90 (+3.32%)Vol644.91K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
AMPHAmphastar Pharmaceuticals, Inc. Stock news BRIEF-Amphastar Pharmaceuticals Q3 EPS USD 0.87 Reuters
AMPHAmphastar Pharmaceuticals, Inc. Press release Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 PR Newswire
AMPHAmphastar Pharmaceuticals, Inc. Stock news Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 PRNewsWire
AMPHAmphastar Pharmaceuticals, Inc. Stock news Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for Zacks Investment Research
AMPHAmphastar Pharmaceuticals, Inc. Press release Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026 Amphastar Pharmaceuticals, Inc. PR Newswire
AMPHAmphastar Pharmaceuticals, Inc. Stock news Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock? Zacks Investment Research
AMPHAmphastar Pharmaceuticals, Inc. Stock news Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) Defense World
AMPHAmphastar Pharmaceuticals, Inc. Press release Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference PRNewsWire
AMPHAmphastar Pharmaceuticals, Inc. Stock news 3 Generic Drug Stocks to Watch Amid Improving Industry Trends Zacks Investment Research
AMPHAmphastar Pharmaceuticals, Inc. Stock news New Strong Sell Stocks for August 14th Zacks Investment Research
AMPHAmphastar Pharmaceuticals, Inc. Stock news Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript Seeking Alpha
AMPHAmphastar Pharmaceuticals, Inc. Stock news Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics Zacks Investment Research
AMPHAmphastar Pharmaceuticals, Inc. Stock news Amphastar Pharmaceuticals Q2 Earnings Call Highlights MarketBeat
AMPHAmphastar Pharmaceuticals, Inc. Press release Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 PRNewsWire
AMPHAmphastar Pharmaceuticals, Inc. Stock news Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply CNBC
AMPHAmphastar Pharmaceuticals, Inc. Stock news Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag MarketBeat
AMPHAmphastar Pharmaceuticals, Inc. Press release Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference Accesswire
AMPHAmphastar Pharmaceuticals, Inc. Stock news Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook MarketBeat
AMPHAmphastar Pharmaceuticals, Inc. Stock news Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript Seeking Alpha
AMPHAmphastar Pharmaceuticals, Inc. Stock news Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript Seeking Alpha
See more
FAQ

Questions about Amphastar Pharmaceuticals, Inc.

What does Amphastar Pharmaceuticals, Inc. do?
Amphastar Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
What is AMPH's market cap?
Amphastar Pharmaceuticals, Inc. (AMPH) is a listed stock with a live quote. The latest market cap on this page is $1.3B.
Where is Amphastar Pharmaceuticals, Inc. headquartered?
Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, CA.
How do I get AMPH news from the API?
Call GET /v1/news?tickers=AMPH. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does AMPH news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AMPH, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the AMPH price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs